Bellerophon Therapuetics (BLPH) Rockets On COVID-19 Treatment

Bellerophon Therapeutics BLPH Stock News

Bellerophon Therapeutics Inc (NASDAQ: BLPH) is rocketing in the market this morning, trading on gains of more than 500%. The gains come after the company announced that the United States FDA has granted emergency expanded access for the company’s treatment for COVID-19. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

BLPH Stock Rockets On Coronavirus Treatment News

In the press release, the company said that the FDA has granted expanded access for its proprietary inhaled nitric oxide delivery system. The system known as INOpulse may be used immediately for the treatment of COVID-19.

Nitric Oxide, or NO, is a naturally produced molecule that’s critical to the body’s immune response against pathogens and infections. In vitro studies have shown that NO inhibits the replication of SARS-CoV and improves survival for cells infected with the virus.

Moreover, in a clinical study of patients infected with SARS-CoV, iNO demonstrated improvement in arterial oxygenation and a reduction in the need for ventillation support. Moreover, BLPH said that the treatment also leads to an improvement in lung infiltrates observed on chest radiography.

Due to the fact that today’s coronavirus and SARS-CoV are so similar, the data in SARS-CoV support the potential for there to be a meaningful benefit in patients infected with COVID-19.

In a statement, Fabian Tenenbaum, CEO at BLPH, had the following to offer:

Based on currently available data and its significant role in the immune response, we believe INOpulse has the potential to be a safe and effective treatment for COVID-19. INOpulse technology utilizes targeted pulsatile delivery of inhaled nitric oxide, providing important antiviral potential, as well as improved arterial oxygenation. Importantly, INOpulse is designed to treat patients in the outpatient setting, which may be critical in helping combat the further spread of the virus and significantly alleviate the mounting impact on hospitals and intensive care units. We look forward to supporting patients and physicians in order to help address the current COVID-19 global health pandemic.

Why The Stock Is Up 5X

There’s good reason for all of the excitement here. As we all know, the coronavirus is a big deal. As it continues to spread around the world, the medical community is quickly working to find ways to treat the condition. This is where Bellerophon Therapeutics comes in.

With today’s announcement, BLPH became the first company to provide a potentially effective treatment for COVID-19 patients. Considering the severity of the virus, there’s a strong chance that this treatment will be met with incredibly high demand, leading to a dramatic rise in revenue.

All in all, BLPH investors have plenty to look forward to.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.